A Phase II study combining D-1553 with the FAK inhibitor Ifebemtinib in treatment-naive NSCLC patients with KRAS G12C mutations reported an ORR of 87.5% and a DCR of 93.8%, with no additional toxicity compared to monotherapy (62). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.